Hansa’s enzyme therapy study fail Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 17 December, 2025

Share your perspective. Endpoints is fielding the next Biopharma Sentiment Index (BPSI), a three-minute survey that distills thousands of industry views into a quarterly benchmark. It’s one of the clearest snapshots of how people inside biopharma see the year ahead. Add your voice today.

presented by Strength in rar­i­ty: Why biotech spon­sors are dou­bling down on rare on­col­o­gy con­sor­tia

news Harbour makes $90M upfront deal with Bristol Myers for new antibodies DBV charts new path to market peanut allergy patch after Phase 3 success Hansa’s enzyme therapy flunks Phase 3 trial in rare kidney disease GSK wins FDA approval for long-acting asthma drug

Client Engagement Mgr - Life Sciences Strategy & Intelligence Sedulo Group Remote Analyst – Life Sciences Strategy & Intelligence Sedulo Group Remote Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Jan 22 12:00pm ET Scaling for a New Era: The Rise of Radiopharma sponsored by PharmaLogic Dec 17 12:00pm ET Genetic cohorting and therapeutic response in CKD: Real-world insights from RenasightIQ™ sponsored by Natera

ENDPOINTS PHARMA Mythic Therapeutics shuts down, ditching lone ADC trial as funding dries up Verge Genomics' ALS drug fails as biotech shifts to partner model Makary walks back talk of Covid-19 vaccine risk amid internal FDA debate Facing multibillion-dollar patent cliff, Pfizer plans slew of obesity trials FDA extends decision on Aldeyra's dry eye disease drug

in case you missed it 1. Chronic pain biotech emerges with $125M and Vivek Ramaswamy on board 2. Nektar to advance alopecia drug to Phase 3, despite ‘violations’ in trial 3. News Briefing OrsoBio obesity data; Monte Rosa's prostate cancer pill; Development pacts for Adaptive and SandboxAQ 4. J&J backs financing round for Stanford CAR-T cell therapy spinout Link Cell 5. Aeovian gets $55M for tuberous sclerosis complex, to explore prospects in obesity 6. RTW startup signs autoimmune antibody pact with China’s GenSci